![]() ![]() Guest editor for a Methods issue (a companion journal to Methods in Enzymology) entitled “Humanized Antibodies and Their Applications” (May 2005).Editorial Board, mAbs journal (2008-present).Member of Industrial Advisory Board, Institute for Applied Life Sciences (IALS), University of Massachusetts, Amherst (2016-present).Member of Scientific Advisory Board of the Development Center for Biotechnology (DCB) of Taiwan, a government-sponsored nonprofit organization (2014-present).Professional Appointments and Activities.National Taiwan University, Taipei, Taiwan, R. In addition, he has helped build hundreds of biologics in research and development with >80 programs moved into clinical development. Herren is also a co-inventor for inebilizumab and anifrolumab. (7) anti-IL-13 antibody (Adbry™ tralokinumab) for atopic dermatitis. ![]() (5) anti-type I interferon receptor antibody (Saphnelo™, anifrolumab) for systemic lupus erythematosus (6) Evusheld™ (tixagevimab and cilgavimab), long-acting antibody combination for both prevention and treatment of COVID-19. His work has led to seven market approved biologics: (1) anti-PD-L1 antibody (Imfinzi® durvalumab) for cancer treatment (2) anti-IL-5α receptor antibody (Fasenra® benralizumab) for severe eosinophilic asthma treatment (3) anti-CD22 immunotoxin (LumoxitiTM moxetumomab pasudotox) for hairy cell leukaemia (4) anti-CD19 antibody (UPLIZNA™ inebilizumab-cdon) for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD). Played a key role in building AstraZeneca’s and MedImmune’s biologics pipeline for cancers, respiratory diseases, autoimmune diseases, inflammation, cardiovascular and metabolic diseases, infectious diseases and CNS/pain.Was responsible for AstraZeneca’s and MedImmune’s global biologic drug discovery and technology including antibody discovery, antibody/protein engineering, antibody-drug conjugates, bi-specifics/multi-specifics, therapeutic peptides, protein scaffolds, protein sciences, proteomics/metabolomics, structural biology, in vivo expressed biologics (AAV gene therapy, cell therapy and RNA/DNA therapy), and cell line generation.50 issued US patents related to antibody/protein therapeutics and technologies.29-year experience in biologic drug discovery and development. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |